Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Other Non-Current Assets (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Other Non-Current Assets for 10 consecutive years, with $522000.0 as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 12.5% to $522000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $522000.0 through Dec 2025, up 12.5% year-over-year, with the annual reading at $522000.0 for FY2025, 12.5% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $522000.0 at Rhythm Pharmaceuticals, down from $671000.0 in the prior quarter.
  • The five-year high for Other Non-Current Assets was $671000.0 in Q3 2025, with the low at $328000.0 in Q1 2021.
  • Average Other Non-Current Assets over 5 years is $398300.0, with a median of $328000.0 recorded in 2021.
  • The sharpest move saw Other Non-Current Assets dropped 18.61% in 2021, then soared 45.24% in 2025.
  • Over 5 years, Other Non-Current Assets stood at $328000.0 in 2021, then changed by 0.0% to $328000.0 in 2022, then changed by 0.0% to $328000.0 in 2023, then skyrocketed by 41.46% to $464000.0 in 2024, then rose by 12.5% to $522000.0 in 2025.
  • According to Business Quant data, Other Non-Current Assets over the past three periods came in at $522000.0, $671000.0, and $527000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.